Press Releases :: Pelthos Therapeutics Inc. (PTHS)

Skip to main content Skip to section navigation Skip to footer

Jul 10, 2025 8:00 am EDT

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

Jul 2, 2025 7:00 am EDT

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Jun 27, 2025 9:15 am EDT

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

May 14, 2025 8:00 am EDT

Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

May 1, 2025 5:00 pm EDT

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

Apr 17, 2025 6:00 am EDT

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Dec 20, 2024 9:00 am EST

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

Dec 18, 2024 8:30 am EST

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Nov 21, 2024 9:49 am EST

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Oct 29, 2024 8:30 am EDT

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Select a page